cytochrome c oxidase subunit 6A1Genealiases: CMTRID · COX6A · COX6AL
Q-omics provides the consensus-scored COX6A1 profile across patient tissues and cancer cell-line models. COX6A1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, COX6A1 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, COX6A1 protein abundance shows 31,806 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, BLCA, and LUAD as cancer lineages where COX6A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COX6A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COX6A1 survival associations across molecular data types. COX6A1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COX6A1 RNA expression–survival associations across cancer types. High COX6A1 expression shows unfavorable associations in UVM, SKCM, KIRC, ACC, LIHC and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for COX6A1 RNA expression.
This table summarizes COX6A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 11. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for COX6A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COX6A1 shows higher tumor expression in BLCA, LIHC, KIRP, HNSC, BRCA and LUSC. The BLCA box plot shows higher COX6A1 RNA expression in tumor versus normal tissue (log2 FC = +0.560, t-test p < 0.001).
This table shows molecular features associated with COX6A1 in patient tissues and cancer cell lines. In patient samples, COX6A1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, COX6A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
